Inactive Instrument

Global Blood Therapeutics, Inc.

Equities

GBT

US37890U1088

Biotechnology & Medical Research

GLOBAL BLOOD THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)

March 03, 2020 at 08:11 am EST

ack 1pt solid">

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Latest news about Global Blood Therapeutics, Inc.

BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment	22-10-06	MT
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Global BMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P TMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Biotechnology Select Industry Index	22-10-06	CI
Global Blood Therapeutics, Inc. Announces Cessation of Ted W. Love as Chief Executive Officer	22-10-05	CI
Global Blood Therapeutics, Inc. Announces Executive Changes	22-10-05	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index	22-10-05	CI
Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc. from a group of shareholders.	22-10-04	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Biotechnology Index	22-10-04	CI
Insider Sell: Global Blood Therapeutics	22-09-07	MT
Insider Sell: Global Blood Therapeutics	22-08-19	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
North American Morning Briefing : Caution -2-	22-08-10	DJ
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	22-08-09	MT
SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target	22-08-09	MT
Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66	22-08-09	MT
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adjusts Price Target to $68.50 From $75	22-08-09	MT
William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-09	MT
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67	22-08-09	MT
North American Morning Briefing : Stocks to -2-	22-08-09	DJ
BioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood Therapeutics	22-08-09	MT
Guggenheim Downgrades Global Blood Therapeutics to Neutral From Buy, Sets $68.50 Price Target	22-08-08	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	22-08-08	DJ
Oppenheimer Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-08	MT
Wedbush Downgrades Global Blood Therapeutics to Neutral From Outperform on Pfizer Acquisition, Lowers PT to $68.50 From $74	22-08-08	MT

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.81%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

1st Jan change

Capi.

IQVIA HOLDINGS INC.